金十数据6月23日讯,百奥泰公告,公司与SteinCares签署授权许可及生产、供货和商业化协议,将BAT2406注射液在巴西及其他拉丁美洲市场的独占商业化权益许可给Stein。协议总金额最高至1000万美元,其中包括100万美元首付款和累计不超过900万美元里程碑付款。同时,百奥泰将根据协议约定的净销售额的两位数百分比获得收入分成。协议自双方签订后生效,初始期限为十五年。协议的签署预计将对公司未来业绩产生积极影响。
Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to
Disclaimer.